Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

Cases of influenza continue to soar across Canada, meanwhile rates of respiratory syncytial virus, or RSV, and COVID-19 are ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an investigational oral antiviral candidate targeting Respiratory Syncytial Virus ...

During the COVID pandemic, RSV showed a slightly odd pattern: like flu, it basically disappeared in the 2020–2021 season, ...

Confronting a bird flu outbreak in nature presents unique challenges, as infected animals leave a landscape contaminated, Pa.

In the wake of multiple cases of human metapneumovirus (hMPV) in India, multiple questions about its causes and symptoms seem ...

(Alliance News) - hVIVO PLC on Monday said it has signed a contract with Inhalon Biopharma Inc to test its antiviral candidate to treat respiratory syncytial virus. The London-based contract research ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.